Spain and Italy have limited the use of the AstraZeneca COVID-19 vaccine to people over the age of 60, potentially slowing down the European Union’s sluggish vaccination program, which lags behind Countries include the US, UK and Israel.
vaccines and very rare cases of blood clotting problems in adults. EMA recommends not to limit age, as it emphasizes that the benefits of shooting outweigh the risks.
The Italian Ministry of Health recommends that the vaccine be used only for people over the age of 60, but says those under 60 who received the first dose of AstraZeneca can also get a second dose.
Last month, and French German health official Limit the use of AstraZeneca injections to those over 55 and over 60 years of age, following concerns about abnormal clotting in some recipients.
Earlier on Wednesday, the United Kingdom’s Joint Commission on Immunization and Immunization (JCVI) changed vaccine guidelines, recommending everyone to Under 30 are offered alternative injections, such as the one developed by BioNTech biotechnology
One, due to the rare “disappearance” side effect of the blood clot in the brain.
Shares of AstraZeneca rose 2.04% in Thursday morning trading in London. Stocks have fallen less than 1% this year, according to data from FactSet.
The decision by Spain and Italy to limit the use of injections may make it difficult for the EU to reach its vaccination goal 70% Its mature population in late summer.
The 27-member bloc failed to reach the first milestone of at least 80% of people over the age of 80 and 80% of health workers receiving the COVID-19 preventive vaccine at the end of March, according to the most recent data from European Center for Disease Control and Prevention.
Vaccination rate is likely to increase later this month when Johnson & Johnson Pharmaceuticals
began offering COVID-19 one-shot vaccine to the EU. The bloc has signed a corporate order for 200 million J&J doses and one option for another 200 million.
AstraZeneca on Wednesday acknowledged the findings from the EMA and the UK Health care products and drugs regulatory agency, Note that both reviews “reaffirmed that the vaccine provided a high level of protection against all severity of COVID-19 and these benefits continue to outweigh the risks”.
The Anglo-Swedish pharmaceutical company said it is working with global regulators to better understand individual cases, epidemiology and possible mechanisms that could explain events. This extremely rare.
Particularly on Wednesdays, World Health Organization The Vaccine Safety Advisory Committee said that although the link between the blood clot was “plausible”, it was “unconfirmed” and the cases were “very rare” among the 200 million people vaccinated. AstraZeneca application globally.